View full meeting coverage »

Eyetube Meeting Coverage:

Meeting Coverage Cancun 2017

 

Replay
Cancel

Your 25-second video preview has ended.

to continue watching, please Log In or Register:


Log in / Register

New Drug Class Shows Potential for Glaucoma

  Channels: Glaucoma | Posted 2/5/2017

Jason Bacharach, MD, discussed his excitement regarding results from studies of netarsudil (Aerie), a potential first in a new class of glaucoma medications in 2 decades. The agent was found to be noninferior to timolol in the Rocket 1 and Rocket 2 studies. He also spoke about a fixed-dose agent from the company, PG324, a combination of netarsudil and latanoprost. This would potentially be the first fixed-dose combination drug that contains a prostaglandin available in the United States.


13 / 15 Series: Meeting Coverage Cancun 2017